Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test vs. clinical check: which safely cuts antibiotic use in pneumonia?

NCT ID NCT01723644

Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers compare two approaches to managing antibiotics in adults hospitalized with community-acquired pneumonia. One approach uses doctors' clinical reassessment to decide whether to continue, stop, or change antibiotics. The other uses blood levels of a marker called procalcitonin to guide those decisions. The goal is to see if either strategy can safely reduce how long patients take antibiotics.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
clinical reassessment and procalcitonin-guided antibiotic stewardship
What this could lead to
If the procalcitonin-guided approach works, doctors could safely shorten antibiotic courses for pneumonia, which may reduce side effects and slow the rise of antibiotic resistance.
What could go wrong
Shortening antibiotics based on a blood marker might not be safe for everyone, and some patients could need longer treatment. The trial may not show a clear difference between the two strategies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

286 people

The number who actually took part.

Start date

Oct 2012

Finished

May 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * written informed consent * age ≥ 18 years * admittance from the community or a nursing home with the main diagnosis of community-acquired pneumonia justifying urgent antibiotherapy prescription, hospitalization for at least 6 hours after randomization and chest radiograph compatible with the diagnosis of CAP( Community acquired pneumonia ) Exclusion criteria * the inability to give written informed consent * hospitalization \>24 hours * aspiration pneumonia * nosocomial pneumonia * purulent pleurisy * exacerbation of COPD (chronic obstructive pulmonary disease) * neutropenia (\<1G/L cells) * chronic infection with current antibiotherapy * antibiotherapy before admission for the current infection * immunosuppression (including prolonged corticotherapy (10 mg of prednisone per day for at least one month) * active neoplastic disease, organ transplant, pregnancy, HIV diagnosis with a CD4 count\<200 cells/μL.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Community-acquired pneumonia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Community-Acquired Pneumonia pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Community-acquired pneumonia

Contacts and locations

Locations

  • CHD Vendée

    La Roche-sur-Yon, France

  • CHU de Nantes

    Nantes, France

  • University Hospital of Angers

    Angers, France

  • University Hospital of Bichat Paris

    Paris, France

  • University Hospital of Bobigny Paris

    Paris, France

  • University Hospital of Brest

    Brest, France

  • University Hospital of Clermont-Ferrand

    Clermont-Ferrand, France

  • University Hospital of Grenoble

    Grenoble, France

  • University Hospital of Hôtel-Dieu Paris

    Paris, France

  • University Hospital of Lille

    Lille, France

  • University Hospital of Rennes

    Rennes, France

  • University Hospital of Saint Antoine Paris

    Paris, France

  • University Hospital of Strasbourg

    Strasbourg, France

  • University Hospital of Tours

    Tours, France

  • University hospital of Agen

    Agen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.